Ambulation, hand function persist in multiple sclerosis with ocrelizumab at 6 years

CHICAGO — Most patients with early active relapsing-remitting MS treated with ocrelizumab did not see worse hand function or ambulation over 6 years, according to data presented at the American Academy of Neurology Annual Meeting. In fact, more patients saw their symptoms get better instead of worse, Robert A. Bermel, MD, staff neurologist at the Mellen Center for Multiple Sclerosis,